DENVER, Colo. (247marketnews.com)-- The biotech tape is entering a catalyst-heavy stretch, with NeOnc Technologies Holdings (NASDAQ:NTHI), Connect Biopharma (NASDAQ:CNTB), Valion Bio (NASDAQ:VBIO), Eli Lilly and Company (NYSE:LLY), Celcuity (NASDAQ:CELC), and Capricor Therapeutics (NASDAQ:CAPR) heading into important stretches, but for very different reasons.
NeOnc: November FDA Meeting Puts NEO212 Under The Microscope
NeOnc (NASDAQ:NTHI) is moving toward a November 17, 2026, in-person End-of-Phase 1 Type B meeting with the U.S. Food and Drug Administration concerning NEO212, the company's investigational oral perillyl alcohol-temozolomide conjugate for central nervous system cancers. NeOnc says it plans to seek FDA feedback on the proposed patient population, Phase 2 design, endpoints, dose selection and the evidence potentially needed to support a future marketing application. The company has also said the discussion could address potential regulatory pathways.
NEO212 arrives at that meeting with its Phase 1 dose-escalation work completed. NeOnc has identified 610 mg as its recommended Phase 2 dose after escalation reached a protocol-defined maximum tolerated dose of 810 mg. The company has highlighted individual observations from the early-stage program, including a reported approximately 60% tumor reduction and 21 months of disease control in a patient with recurrent IDH1-wild-type, MGMT-methylated glioblastoma.
The NEO212 story is running alongside a second potential regulatory catalyst for NEO100. In August, NeOnc reported topline Phase 2a results in recurrent or progressive Grade III and Grade IV IDH1-mutant glioma. The company reported six-month progression-free survival of 48.9% versus a prespecified 20% benchmark, with p=0.0047, median overall survival of 26.09 months and 86.7% of patients alive at six months. Five of 24 patients remained on treatment at the data cutoff, according to the company. NeOnc said it planned to seek FDA alignment on a potential registrational path.
The corporate and financing picture has also shifted quickly. NeOnc completed a $15 million registered direct offering in September at $4.20 per share with accompanying warrants. The company subsequently announced redemption of all outstanding Series A convertible preferred shares. Meanwhile, executives disclosed approximately $629,000 in open-market purchases following the NEO100 data, including CEO Amir Heshmatpour's additional 35,000-share purchase for approximately $115,400 on September 15.
Connect Biopharma: COPD Data Throws New Phase 3 Catalyst On the Board
Connect Biopharma (NASDAQ:CNTB) has added another major catalyst to its rademikibart development story with preliminary topline data from the Phase 2 Seabreeze STAT COPD study. In 159 adults with COPD, type 2 inflammation and eosinophil counts of at least 300 cells/μL, Connect reported an 81% reduction in treatment failure through four weeks compared with placebo, with a reported p-value of 0.0122. The company also reported an 85% reduction in new moderate-to-severe COPD exacerbations and a 100% reduction in new emergency-department visits or hospitalizations for new exacerbations through Week 4.
The treatment-failure result is particularly relevant because treatment failure was the study's primary endpoint. Connect reported 11 treatment failures among 81 placebo patients versus two among 78 patients receiving rademikibart in its preliminary analysis. A separate analysis limited to the first 28 days showed a 77% reduction in treatment-failure events, with p=0.0373. The company also reported a 70 mL greater improvement in post-bronchodilator FEV1 at Week 4, although that comparison was not statistically significant, with p=0.1607.
The COPD readout follows September results from the companion Seabreeze STAT asthma study. In that trial, Connect reported a 66% reduction in treatment failure at 28 days and a statistically significant 130 mL improvement in post-bronchodilator FEV1 at Day 7 versus placebo. The asthma treatment-failure endpoint itself did not reach statistical significance, with p=0.153. Connect had previously said it intended to engage with the FDA following the COPD data to seek alignment on a Phase 3 program.
CEO Barry Quart has described the COPD findings as “overwhelming evidence of the potential benefit” of early rademikibart treatment. The company now faces the next layer of development work: regulatory discussions, Phase 3 design and the larger dataset required to determine whether the Phase 2 signal can be reproduced. Connect reported in August that its cash runway was expected to extend for at least one year from that release, giving the company additional room to pursue its clinical plans.
Valion Bio: Needle-Free Entolimod Program Opens New Front
Valion Bio, Inc. (NASDAQ:VBIO) is pursuing a very different biotech opportunity by attempting to change how Entolimod could potentially be administered. On September 30, Valion and Shear Kershman Laboratories announced completion of formulation work for an oral mucosal version of Entolimod using SKL's BioViscid delivery platform. The approach is designed to deliver the investigational biologic through the oral mucosa instead of through an injection, creating a potential second development pathway for the program.
The appeal is largely about deployment. Acute radiation syndrome can present an unusual medical-logistics problem in a radiological or nuclear emergency, where speed, storage, administration and the availability of trained personnel can all become important considerations. Valion's next development question is whether the oral mucosal formulation can produce measurable systemic exposure in the bloodstream and establish a pharmacokinetic profile that supports continued development..
Entolimod's broader development history provides additional context. Valion has been developing the molecule under the FDA's Animal Rule framework and has pursued programs involving radiation-induced hematopoietic and gastrointestinal injury. The company has also reported collaboration involving the Armed Forces Radiobiology Research Institute and NIAID concerning an efficacy protocol for gastrointestinal acute radiation syndrome. In August, Valion announced that Ukraine's Ministry of Health had accepted its Entolimod dossier for formal review under that country's Regulatory Equivalence Pathway.
The company is simultaneously reshaping its corporate infrastructure. Dean Zikria is serving as interim CEO, while Valion continues development of Entolimod and the next-generation TLR5 agonist Entolasta. Its Velocity Bioworks subsidiary also provides an internal biomanufacturing capability. The oral mucosal program therefore adds another potential dimension to a business already pursuing radiation countermeasures, oncology-related applications and manufacturing capabilities.
Eli Lilly: Retatrutide Data Raises Stakes in Obesity Drug Race
Eli Lilly and Company (NYSE:LLY) has produced one of the sector's biggest clinical headlines with detailed Phase 3 TRIUMPH-2 results for investigational retatrutide. At 80 weeks, participants receiving 12 mg of retatrutide averaged a 20.8% reduction in body weight, equivalent to 49.6 pounds. The 9 mg group averaged 19.1% weight loss and the 4 mg group 12.7%, compared with 4.0% for placebo. Among participants with a baseline BMI of at least 35, the 12 mg group averaged a 23.4% reduction, or 60.8 pounds.
The glycemic results add another dimension. Lilly reported average A1C reductions of 1.4%, 1.6% and 1.5% with the 4 mg, 9 mg and 12 mg doses, respectively, compared with 0.2% for placebo. At the 12 mg dose, 39.3% of participants reached an A1C below 5.7%, while 52.0% achieved at least 20% weight loss. Lilly also reported reductions in triglycerides, non-HDL cholesterol, systolic blood pressure, waist circumference and high-sensitivity C-reactive protein.
Retatrutide remains investigational, meaning the clinical results are not equivalent to regulatory approval. Lilly says it plans to submit a Biologics License Application to the FDA in the first quarter of 2027. The company is studying retatrutide across multiple Phase 3 programs covering obesity, type 2 diabetes, obstructive sleep apnea, knee osteoarthritis pain, cardiovascular and renal outcomes, and metabolic dysfunction-associated steatotic liver disease. The initial TRIUMPH program has enrolled more than 5,800 participants, according to Lilly.
At the same time, Lilly is building an increasingly broad cardiometabolic franchise around products already on the market. Zepbound remains an established injectable obesity treatment, while Foundayo (orforglipron) represents Lilly's oral GLP-1 offering. That means the company's retatrutide strategy is not occurring in isolation: it is being developed within a portfolio spanning multiple mechanisms, delivery methods and stages of commercialization.
Celcuity: REVTORPYK Moves from Biotech Story to Commercial Launch
Celcuity Inc. (NASDAQ:CELC) has crossed a major line that many development-stage biotechnology companies spend years trying to reach: its lead drug, REVTORPYK (gedatolisib), is moving into commercial availability in the United States. The FDA approved REVTORPYK on July 14, 2026, for adults with HR-positive/HER2-negative locally advanced or metastatic breast cancer without a detected PIK3CA mutation following progression on or after at least one line of endocrine therapy in the metastatic setting.
The approval covers REVTORPYK in combination with fulvestrant, with or without palbociclib. Celcuity describes gedatolisib as a pan-PI3K and mTORC1/2 inhibitor designed to inhibit all four class I PI3K isoforms as well as both mTOR complexes. In the PIK3CA wild-type cohort of the Phase 3 VIKTORIA-1 trial, Celcuity reported that the REVTORPYK triplet reduced the risk of disease progression or death by 76% compared with fulvestrant, while the doublet reduced that risk by 67%.
The company has also moved rapidly to build its commercial infrastructure. Celcuity said in August that REVTORPYK was on track for a late-third-quarter commercial launch, while the National Comprehensive Cancer Network had included the regimen as a preferred Category 1 second-line or subsequent-line therapy for the relevant patient population. The company also established an expanded-access program ahead of commercial availability.
The next potential expansion is already in motion. In August, Celcuity submitted a supplemental New Drug Application to the FDA for REVTORPYK in HR-positive/HER2-negative advanced breast cancer with PIK3CA mutations, based on results from the mutant cohort of VIKTORIA-1. The company reported that this cohort achieved its primary endpoint, potentially creating a path to expand the addressable population if the FDA approves the application.
Capricor Therapeutics: FDA Countdown Collides with Crucial DMD Data Window
Capricor Therapeutics, Inc. (NASDAQ:CAPR) is entering a particularly consequential period for deramiocel, its investigational cell therapy for Duchenne muscular dystrophy. The FDA has set a new PDUFA target action date of November 22, 2026, after extending the previous August 22 date. Capricor submitted an amendment to its BLA containing additional Phase 3 HOPE-3 data, including 24-month open-label extension information and additional robustness analyses, while proposing a refined indication focused on upper-limb function.
The FDA's review follows a July advisory committee meeting, making the November date the next major regulatory marker for investors. Capricor has emphasized the primary endpoint of HOPE-3, upper-limb function, while continuing to provide longer-term follow-up data. The company's second-quarter update said the HOPE-3 results had been published in The Lancet and that the primary endpoint was achieved with p=0.029.
The company is also using the current World Muscle Society Congress as another data-development opportunity. Capricor is presenting HOPE-3 and open-label-extension data in Hiroshima from September 29 through October 3, including a late-breaking analysis involving delayed-start and natural-history comparisons. The company has also scheduled an October 3 oral presentation covering HOPE-3 Phase 3 results and evidence supporting both musculoskeletal and cardiac efficacy.
Capricor's pipeline extends beyond deramiocel, with its broader platform focused on allogeneic cardiosphere-derived cells and exosome-based therapeutics. The company is also presenting research involving engineered muscle-targeting extracellular vesicles for micro-dystrophin delivery and work involving Pompe disease. Those programs are considerably earlier than the deramiocel regulatory process, however, leaving the November FDA decision as the dominant near-term corporate catalyst.
About 24/7 Market News
In today's fast-moving markets, visibility is everything and 24/7 Market News (24/7) provides a powerful suite of investor relations and public relations solutions designed to elevate your company’s profile quickly and effectively. Whether you're an established name seeking broader awareness, or a micro-cap looking to break out of obscurity, 24/7 delivers targeted, high-impact coverage through timely news distribution, analyst report placements, featured editorials, and multi-channel amplification across financial platforms, social media, and investor communities. Our services help cut through the noise, attract institutional interest, drive exposure, and build long-term shareholder credibility, all while maintaining full SEC compliance and transparency. For Analyst Report coverage, custom IR campaigns, press release syndication, or other tailored investor and public relations solutions, contact [email protected] to discuss how 24/7 can help accelerate your company’s visibility and valuation trajectory.
PAID EDITORIAL DISCLOSURE: This is a paid editorial communication intended for informational purposes only. 24/7 is compensated by NTHI to provide ongoing news coverage of expected upcoming catalysts and events as well as market outreach services. For further disclosure information, please click here. This should not be construed as financial or investment advice. Trading involves substantial risk; consult your financial advisor.
Important Editorial Note: 247 highlights companies approaching significant catalysts and inflection points. This report reflects information available at the time of publication. Since developments can occur rapidly, readers should independently verify current information and review all company filings and disclosures.
CONTACT:
24/7 Market News
[email protected]
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding the Company's ability to grow its business and other statements that are not historical facts, including statements which may be accompanied by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Actual results could differ materially from those described in these forward-looking statements due to a number of factors, including without limitation, the Company's ability to continue as a going concern, general economic conditions, and other risk factors detailed in the Company's filings with the SEC. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake any responsibility to update such forward-looking statements except in accordance with applicable law.